Pharma & Biotech

A notable shift is occurring within the shareholder base of medical technology firm Fractyl Health. Specialized investment firms are accumulating...

As mid-March 2026 approaches, Reflect Scientific enters a pivotal period. The company faces the essential challenge of demonstrating it can...

Pfizer's ambitious portfolio transformation is beginning to yield tangible results. A significant milestone was achieved with the recent regulatory approval...

Major investment firms are building significant positions in Danaher Corporation, signaling confidence in the life sciences and diagnostics specialist despite...

As March 2026 unfolds, Innoviva continues to solidify its standing within the specialized healthcare market. Investor attention is pivoting toward...

Sangamo Therapeutics is advancing decisively with its investigational gene therapy, ST-920, for Fabry disease. The company has submitted critical data...

Anixa Biosciences continues to advance its oncology pipeline, supported by encouraging clinical data and a shareholder-endorsed management team. Recent developments...

Following a robust performance in fiscal 2025, Legend Biotech Corp is on the cusp of reaching profitability. Company leadership projects...

While Valneva prepares to release its full-year 2025 financial results this Tuesday, investor focus is firmly fixed elsewhere. The upcoming...

A significant clinical milestone has been reached in the treatment of generalized anxiety disorder (GAD), a condition affecting over 20...